Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment

[1]  M. Egger,et al.  Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. , 2005, International journal of epidemiology.

[2]  E. Schouten,et al.  Scaling up HIV/AIDS and joint HIV-TB services in Malawi. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  L. Ferradini,et al.  Simplifying and adapting antiretroviral treatment in resource-poor settings: a necessary step to scaling-up. , 2004, AIDS.

[4]  H. Whittle,et al.  Body Mass Index at Time of HIV Diagnosis: A Strong and Independent Predictor of Survival , 2004, Journal of acquired immune deficiency syndromes.

[5]  P. Price,et al.  Immune restoration disease after antiretroviral therapy , 2004, AIDS.

[6]  Katharina Kober,et al.  Scaling up access to antiretroviral treatment in southern Africa: who will do the job? , 2004, The Lancet.

[7]  M. Peeters,et al.  Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial , 2004, The Lancet.

[8]  D. Kuritzkes.  Extending antiretroviral therapy to resource-poor settings: implications for drug resistance , 2004, AIDS.

[9]  D. Kuritzkes,et al.  What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection , 2004, AIDS.

[10]  A. Boulle,et al.  Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa , 2004, AIDS.

[11]  P. Farmer,et al.  Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience , 2004, AIDS.

[12]  M. Vitoria,et al.  Antiretroviral treatment in resource-poor settings: the Brazilian experience , 2004, AIDS.

[13]  M. Kazatchkine,et al.  Drug resistance and adherence to HIV/AIDS antiretroviral treatment: against a double standard between the north and the south , 2004, AIDS.

[14]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[15]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[16]  T. Flanigan,et al.  The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India , 2003, AIDS.

[17]  A. Zolopa,et al.  High levels of adherence do not prevent accumulation of HIV drug resistance mutations , 2003, AIDS.

[18]  E. Hudes,et al.  Dramatic improvement in survival among adult Brazilian AIDS patients , 2003, AIDS.

[19]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[20]  D. Bangsberg,et al.  Adherence is not a barrier to successful antiretroviral therapy in South Africa , 2003, AIDS.

[21]  Jane Galvão,et al.  Access to antiretroviral drugs in Brazil , 2002, The Lancet.

[22]  J. Frater.  The impact of HIV-1 subtype on the clinical response on HAART. , 2002, Journal of HIV therapy.

[23]  D. Spiegelman,et al.  Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. , 2002, Journal of acquired immune deficiency syndromes.

[24]  J. Moatti,et al.  Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study , 2002, Antiviral therapy.

[25]  P. Weidle,et al.  Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance , 2002, The Lancet.

[26]  F. Liégeois,et al.  The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study , 2002, AIDS.

[27]  M. Alvarez,et al.  Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. , 2002, The Journal of infectious diseases.

[28]  Sundhiya Mandalia,et al.  Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome , 2002, AIDS.

[29]  J. Moatti,et al.  The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort , 2001, Journal of acquired immune deficiency syndromes.

[30]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[31]  K. Hertogs,et al.  High Prevalence of Genotypic and Phenotypic HIV‐1 Drug‐Resistant Strains Among Patients Receiving Antiretroviral Therapy in Abidjan, Côte d'lvoire , 2001, Journal of Acquired Immune Deficiency Syndromes.

[32]  P. Massip,et al.  Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen , 2000, AIDS.

[33]  A. Wu,et al.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.

[34]  G. Salama,et al.  Using RT-PCR and bDNA assays to measure non-clade B HIV-1 subtype RNA. , 1999, Journal of virological methods.

[35]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[36]  James Curran,et al.  Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach , 2005 .

[37]  R. Geskus,et al.  Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. , 2003, Ethiopian medical journal.